key: cord-0958210-bjj8wp9y
authors: Umair, M.; Salman, M.; Rehman, Z.; Badar, N.; Ahad, A.; Ikram, A.
title: An upsurge of SARS CoV-2 B.1.1.7 Variant in Pakistan
date: 2021-03-05
journal: nan
DOI: 10.1101/2021.02.26.21252562
sha: 7a6ee422430206990e337346d8c74b959ca7fc1a
doc_id: 958210
cord_uid: bjj8wp9y

The emergence of a more transmissible variant of SARS-CoV-2 (B1.1.7) in the United Kingdom (UK) during late 2020 has raised major public health concerns. Several mutations have been reported in the genome of the B.1.1.7 variant including the N501Y and 69-70deletion in the Spike that has implications on virus transmissibility and diagnostics. Although the B.1.1.7 variant has been reported from several countries, only two cases have been identified through whole-genome sequencing from Pakistan. We used a two-step strategy for the detection of B.1.1.7 with initial screening through ThermoFisher TaqPathTM SARS-CoV-2 kit followed by partial sequencing of Spike (S) gene of samples having spike gene target failure (SGTF) on real-time PCR. From January 01, 2021, to February 21, 2021, a total of 2,650 samples were tested for the presence of SARS-CoV-2 using TaqPathTM kit and 70.4% (n=1,867) showed amplification of all the 3 genes (S, N, and ORF). Notably, 29.6% (n=783) samples had the spike gene target failure (SGTF). The SGTF cases were detected at a low frequency during the first three weeks of January (n=10, n=13, and n=1 respectively) however, the cases started to increase in the last week. During February, 726 (93%) cases of SGTF was reported with a peak (n=345) found during the 3rd week. Based on the partial sequencing of spike gene of SGTF samples (n=15), 93% (n=14) showed the characteristic N501Y, A570D, P681H, and T716I mutations found in the B.1.1.7 variant. Our findings highlight the high prevalence of B.1.1.7 in Pakistan and warrant large scale genomic surveillance and strengthening of laboratory network in the country.

The last few months of 2020 have witnessed the emergence of different variants of severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) having characteristic mutations in their genome [1] . One such variant is the B.1.1.7 (VOC 202012/01) which was first detected in the United Kingdom (UK) during November 2020, later rapidly became one of the most prevalent form of SARS-CoV-2 in the country. Due to its high transmissibility rate (about 50-70%) [2] , the variant has now spread to 93 countries as of February 21, 2021 [3] .

The B.1.1.7 harbors 17 amino acid changes mostly in the Spike (S) protein (69-70del, 144del, N501Y, A570D, P681H, T716I, S982A and D1118H) [4] . Mutations in the S protein of SARS-CoV-2, which is involved in viral entry into host cells can potentially impact virus transmissibility, diagnostic capability and pathogenesis. Of particular note is the N501Y change in the receptor binding domain (RBD) that is directly involved in interactions with the human angiotensin-converting enzyme 2 (hACE2) receptor [5] . The N501Y mutation can lead to enhanced viral binding efficiency with hACE2 thus rendering the virus more transmissible [6, 7] .

Similarly, the 69-70 deletion (del69-70) in the S gene may increase cell infectivity and lead to diagnostic failure in real-time PCR amplification kits targeting this region [8, 9] . One such assay is the ThermoFisher TaqPath TM SARS-CoV-2 kit that targets three genes of the virus including the S gene [10] . With this method, the del69-70 in the S gene of SARS-CoV-2 results in the spike gene target failure (SGTF) on real-time PCR that has been used as a proxy for the detection of B.1.1.7 variant [9, 11] . Recently, the European CDC and US FDA also recommended that SGFT can be used as signal for early identification of del69-70 that can be further investigated to track mutant virus [12] .

Currently, the genomic surveillance of SARS-CoV-2 in Pakistan is limited to few laboratories having specialized facilities and expertise that has resulted in uncertainty about the introduction, geographic spread and community transmission of variants such as the B.1.1.7. As of 26

February 2021, only two cases of B.1.1.7 have been reported from Pakistan through wholegenome sequencing by the National Institute of Health [13] . We aimed to investigate the prevalence of B.1.1.7 in Pakistan using the SGTF method followed by confirmation of a subset of samples through partial sequencing of S gene (encompassing the RBD).

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

During January 01, 2021 to February 21, 2021, a total of 2,650 samples were tested for the presence of SARS-CoV-2 on real-time PCR using TaqPath TM kit. Among the total samples, 70.4% (n=1,867) showed amplification of all the 3 genes (S, N, and ORF). Notably, 783 (29.6%) samples had the spike gene target failure (SGTF). These SGTF cases were detected at a low frequency during the first three week of January (n=10, n=13 and n=1 respectively) however, the cases started to increase in the last week. During February, 726 (93%) cases of SGTF were reported with a peak (n=345) found during the 3 rd week (Fig. 1) .

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 5, 2021 [16, 17] .

Therefore, we used partial sequencing of S gene on a subset of SGTF samples as a confirmatory . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 5, 2021 The small size representative of a defined geographic area is a major limitation of the study.

However, our findings highlight the possible spread of the B.1.1.7 in indigenous population and warrants large scale genomic surveillance. Moreover, it will guide health authorities to take appropriate measures to prevent further spread of the variant in the country.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. We declare no competing interests.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 5, 2021. ; https://doi.org/10.1101/2021.02.26.21252562 doi: medRxiv preprint

Genetic Variants of SARS-CoV-2-What Do They Mean?

New variant of SARS-CoV-2 in UK causes surge of COVID-19

Tracking the international spread of SARS-CoV-2 lineages B.1.1.7 and B.1.351/501Y-V2

Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations

SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies

Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-2 in the United Kingdom

Quantifying the transmission advantage associated with N501Y substitution of SARS-CoV-2 in the United Kingdom: An early data-driven analysis

Neutralising antibodies in Spike mediated SARS-CoV-2 adaptation. medRxiv

Public health actions to control new SARS-CoV-2 variants

Comparison of 12 Molecular Detection Assays for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Genetic Variants of SARS-CoV-2 May Lead to False Negative Results with Molecular Tests for Detection of SARS-CoV-2 -Letter to Clinical Laboratory Staff and Health Care Providers

Importation of SARS CoV 2 Variant B. 1.1. 7 in Pakistan

Rapid, Sensitive, Full-Genome Sequencing of Severe Acute Respiratory Syndrome Coronavirus 2. Emerg Infect Dis

Identification of a novel SARS-CoV-2 Spike 69-70 deletion lineage circulating in the United States

Detection of non-B.1.1.7 Spike ∆ 69/70 sequences (B.1.375) in the